Posts

No recent news about former employee suing BioNTech for cutting corners in pancreatic cancer trials found in current search results. The available information does not mention any such lawsuit or allegations related to BioNTech or pancreatic cancer trials involving a former employee. Thus, there is no recent news on this specific claim at this time.

on

Despite 'decent' data, Verastem rethinks options for approved oncology combo in pancreatic cancer

on

Elicio pancreatic cancer vaccine misses Phase II primary endpoint but shows post-hoc signal in resected patients

on

WOW!: RevMed and Tango’s pancreatic cancer combo achieves 92% response

on

Revolution Medicines Confident in RAS Leadership as Rivals Square Up: Recent News Summary (June 2026)

on

All eyes on Revolution, bispecific antibodies and more at ASCO26

on

Can Revolution's miracle pancreatic cancer drug be topped? Immuneering, Actuate say yes – BioSpace, Stat News, and clinical trial updates, May 2026

on

Revolution Medicines Buyout Valuation Post-Phase 3: Talks Collapse at $30B

on

Pivotal Pancreatic Cancer Data Fuels Revolution Medicines' Upsized $2B Offering

on

Revolution Medicines' Daraxonrasib Doubles Survival in Phase 3 Pancreatic Cancer Trial

on

Revolution Medicines Advances Daraxonrasib in Phase 3 Pancreatic Cancer Trial After Hitting Key Goals

on

Amplia Therapeutics Reports Four Additional Complete Responses and Improved Survival in ACCENT Pancreatic Cancer Trial

on

Narmafotinib Large-Scale Manufacture Complete by Amplia Therapeutics

on

Oncolytics Biotech Expands GI Tumor Scientific Advisory Board with Eileen O’Reilly, Neil Segal, and Van Morris

on

Pfizer Reduces Stake in BioNTech; Candel Pauses Pancreatic Cancer Program

on

Federally-Funded Cancer Research at a Perilous Crossroads: Deep Cuts Threaten Progress

on

Actuate Therapeutics' Pancreatic Cancer Drug Elraglusib Shows Survival Benefit in Phase 2 Study

on

OSE Immunotherapeutics Reports 65% Overall Survival Rate in Phase 2 Cancer Vaccine Trial at ASCO 2025

on